Since publication of the last full practice guideline and guideline watch on schizophrenia, there have been a multitude of studies on new pharmacological and nonpharmacological treatments for schizophrenia.
Researchers conducted a systematic review and meta-analysis to assess the incidence and predictors of psychosis relapse in individuals receiving treatment with antipsychotic agents.
Research was conducted to assess the impact of initiation of treatment with second-generation antipsychotics and treatment interruptions on weight gain in patients with schizophrenia and bipolar 1 disorder.
Polygenic risk scores predict the progression from unipolar depression to bipolar or psychiatric disorders.
Compared with usual treatment, the use of long-acting injectable antipsychotics significantly increased the time to first hospitalization in patients with early-phase schizophrenia.
The researchers concluded that the correlation between interregional cortical thinning during maturation and expression patterns of genes associated with multiple psychiatric disorders suggested a common molecular process.
Patients with schizophrenia and a history of catatonia had greater deficits in the cognitive domains of immediate memory, verbal fluency, and processing speed compared to patients with schizophrenia alone.
To learn more about SEP-363856 as a novel treatment for schizophrenia, we spoke with Kenneth Koblan, PhD, and John Krystal, MD.
The state has increased telehealth assessments and treatments for patients with psychiatric and addictive disorders through state Medicaid, third party, and federal Medicare and HIPAA waivers.
Patients with bipolar disorder experienced significant reductions in sleep efficiency, which was not the case in patients with schizophrenia, although effect sizes for bipolar disorder were smaller overall.
